XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Long-Term Investments (Tables)
 6 Months Ended
Jun. 30, 2024
Long-Term Investments [Abstract]  
Schedule of Ownership Percentages of Each Investee The ownership percentages of each investee are listed as follows:
   Ownership percentage    
   June 30,   December 31,   Accounting
Name of related party  2024   2023   treatments
Braingenesis Biotechnology Co., Ltd.   0.17%   0.17%  Cost Method
Genepharm Biotech Corporation   0.67%   0.67%  Cost Method
BioHopeKing Corporation   5.90%   5.90%  Cost Method

ForSeeCon Corporation

   

19.78

%   

-

%  Cost Method
BioFirst Corporation   18.68%   18.68%  Equity Method
Rgene Corporation   26.65%   26.65%  Equity Method
Schedule of Extent the Investee Relies The extent the investee relies on the company for its business are summarized as follows:
Name of related party  The extent the investee relies on the Company for its business
Braingenesis Biotechnology Co., Ltd.  No specific business relationship
Genepharm Biotech Corporation  No specific business relationship
BioHopeKing Corporation  Collaborating with the Company to develop and commercialize drugs
ForSeeCon Corporation 

Collaborating with the Company to develop and commercialize ophthalmic medical devices (referring to Note 4, Collaborative Agreements)

BioFirst Corporation  Loaned from investee and provides research and development support service
Rgene Corporation  Collaborating with the Company to develop and commercialize drugs
BioLite Japan K.K.  Prepaid investment for a Joint Venture
Schedule of Long-Term Investment Long-term investment mainly consists of the following:
   June 30,
2024		   December 31,
2023		 
   (Unaudited)     
Non-marketable Cost Method Investments, net        
Braingenesis Biotechnology Co., Ltd.  $6,794   $7,213 
Genepharm Biotech Corporation   20,742    22,021 
BioHopeKing Corporation   770,487    818,018 
ForSeeCon Corporation (See Note 4)   
-
    
-
 
Sub total   798,023    847,252 
Equity Method Investments, net          
BioFirst Corporation   1,579,526    1,680,488 
Rgene Corporation   
-
    
-
 
Total  $2,377,549   $2,527,740 
Schedule of Balance Sheet Balance Sheet
   June 30,
2024		   December 31,
2023		 
   (Unaudited)     
Current Assets  $1,676,014   $1,451,877 
Non-current Assets   606,553    686,206 
Current Liabilities   3,063,359    2,286,058 
Non-current Liabilities   105,548    347,193 
Stockholders’ Equity (Deficit)   (886,340)   (495,168)
   June 30,
2024		   December 31,
2023		 
   (Unaudited)     
Current Assets  $254,967   $50,538 
Non-current Assets   3,258,797    250,716 
Current Liabilities   2,508,301    2,591,960 
Non-current Liabilities   
-
    811 
Shareholders’ Deficit   (1,005,463)   (2,291,517)
Schedule of Statement of Operation Statement of Operations
   Six months Ended
June 30,		 
   2024   2023 
   (Unaudited) 
Net sales  $358   $
-
 
Gross profit   217    
-
 
Net loss   (426,599)   (788,788)
Share of losses from investments accounted for using the equity method   79,057    
-
 
   Six months Ended
June 30,		 
   2024   2023 
   (Unaudited) 
Net sales  $
-
   $
-
 
Gross Profit   
-
    
-
 
Net loss   (78,161)   (155,873)
Share of loss from investments accounted for using the equity method   
-
    
-
 

 
Schedule of Loss on Investment in Equity Securities The components of losses on equity investments for each period were as follows:
   Six months Ended
June 30,		 
   2024   2023 
   (Unaudited) 
Share of equity method investee losses  $79,057   $
        -